Skip to content
10-Q

Quarterly Report

Silexion Therapeutics Corp SLXN SLXNW

0001178913-26-002744

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 4.19M sh
Shares Diluted Q1 2026 · Mar 31, 2026 3.23M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 451.99K sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $6K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.65M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.45M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $2.41M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $5.99M
Stockholders Equity Q1 2026 · Mar 31, 2026 $291K
Stockholders Equity Q1 2026 · Dec 31, 2025 $2.6M
Current Liabilities Q1 2026 · Mar 31, 2026 $4.06M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.76M
Total Liabilities Q1 2026 · Mar 31, 2026 $4.31M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.61M
Total Liabilities Q1 2026 · Mar 31, 2025 $5.72M
Current Assets Q1 2026 · Mar 31, 2026 $4.07M
Current Assets Q1 2026 · Dec 31, 2025 $6.64M
Total Assets Q1 2026 · Mar 31, 2026 $4.6M
Total Assets Q1 2026 · Dec 31, 2025 $7.22M
Total Assets Q1 2026 · Mar 31, 2025 $8.31M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.85
Eps Diluted restated Q1 2026 · Mar 31, 2025 $3.84
Eps Basic Q1 2026 · Mar 31, 2026 $0.85
Eps Basic restated Q1 2026 · Mar 31, 2025 $3.84
Sga Expense Q1 2026 · Mar 31, 2026 $1.38M
Sga Expense Q1 2026 · Mar 31, 2025 $1.06M
Rd Expense Q1 2026 · Mar 31, 2026 $1.37M
Rd Expense Q1 2026 · Mar 31, 2025 $590K
Net Income Q1 2026 · Mar 31, 2026 −$2.73M
Net Income Q1 2026 · Mar 31, 2025 −$1.74M
Operating Income Q1 2026 · Mar 31, 2026 −$2.75M
Operating Income Q1 2026 · Mar 31, 2025 −$1.65M